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Abstract
Background: Clinical studies employ the Unified Parkinson’s Disease Rating Scale (UPDRS) to measure the severity
of Parkinson’s disease. Evaluations often fail to consider the health-related quality of life (HrQoL) or apply disease-
specific instruments. Health-economic studies normally use estimates of utilities to calculate quality-adjusted life
years. We aimed to develop an estimation algorithm for EuroQol- 5 dimensions (EQ-5D)-based utilities from the
clinical UPDRS or disease-specific HrQoL data in the absence of original utilities estimates.
Methods: Linear and fractional polynomial regression analyses were performed with data from a study of
Parkinson’s disease patients (n=138) to predict the EQ-5D index values from UPDRS and Parkinson’s disease
questionnaire eight dimensions (PDQ-8) data. German and European weights were used to calculate the EQ-5D
index. The models were compared by R
2, the root mean square error (RMS), the Bayesian information criterion, and
Pregibon’s link test. Three independent data sets validated the models.
Results: The regression analyses resulted in a single best prediction model (R
2: 0.713 and 0.684, RMS: 0.139 and
13.78 for indices with German and European weights, respectively) consisting of UPDRS subscores II, III, IVa-c as
predictors. When the PDQ-8 items were utilised as independent variables, the model resulted in an R
2 of 0.60 and
0.67. The independent data confirmed the prediction models.
Conclusion: The best results were obtained from a model consisting of UPDRS subscores II, III, IVa-c. Although a
good model fit was observed, primary EQ-5D data are always preferable. Further validation of the prediction
algorithm within large, independent studies is necessary prior to its generalised use.
Keywords: Parkinson’s disease, Quality of life, EuroQoL/EQ-5D, UPDRS, PDQ-8, Prediction
Background
In recent years, increased measurement of health-related
quality of life (HrQoL) has expanded to evaluate chronic
disorders and analyse cost-effectiveness in particular.
Different instruments were developed to assess the
HrQoL. Types of HrQoL instruments include profile-
based instruments that depend on the aggregation of
several outcome values (e.g., Parkinson’s disease ques-
tionnaire eight dimensions (PDQ-8) [1]) and index
instruments with a single index value to represent the
HrQoL (e.g., EuroQol – 5d i m e n s i o n s( E Q - 5 D )[ 2 ] ) .
Disease-specific (e.g., PDQ-8 [1]) and generic instru-
ments (e.g., EQ-5D [2]) are also available.
The guidelines for health-economic evaluations call for
the implementation of quality of life as a patient-relevant
outcome and the use of utility-based patient preferences
[3-5]. However, utility-based instruments are not rou-
tinely applied, even in recent clinical trials. Clinical scales
are regularly used, and study designs frequently include
disease-specific HrQoL or profile instruments.
Cost-utility studies require HrQoL data, and clinical
effectiveness parameters. We aimed to develop a map-
ping algorithm based on Unified Parkinson's Disease
Rating Scale (UPDRS) and PDQ-8 data in cases when
utilities are needed but not assessed in the field of
Parkinson’sd i s e a s e .
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Clinical evaluation
The data were collected from a study population of
patients (n=138) with idiopathic Parkinson’s disease
following recruitment at several study centres in Hessia,
Germany. A detailed description of the patients and
scales applied was previously published [6]. The sever-
ity of Parkinson’s disease was assessed with the UPDRS
[7]. Our analysis relied on subsets to calculate several
scores, including the summed scores of parts II-IV.
The latter data were also divided into subscores for
dyskinesias (IVa), motor fluctuations (IVb), and other
complications (IVc).
The HrQoL was evaluated with the generic EQ-5D and
the disease-specific, profile-based HrQoL Parkinson’s
disease questionnaire in its short version (PDQ-8) [1].
The health states identified by the EQ-5D were converted
into EQ-5D indices employing weights from the German
population valued with the time trade-off approach
(hereafter referred to as the EQ-5D Germanindex) ranging
between 0 and 1 [8], and weights from a pooled Euro-
pean population valued by a visual analogue technique
ranging from 0 to 100 (EQ-5D Europeanindex) [9].
We validated our results with three independent
datasets: (1) our own unpublished data, (2) data from
Siderowf et al. [10], and (3) data from Schrag et al.
[11]. Siderowf et al. reported data for the UPDRS II
and III, the PDQ-8, and the EQ-5D. The data from
Schrag et al. consisted of the EQ-5Dindex, PDQ-8,
and all UPDRS subscores. Our own data included the
EQ-5Dindex and the UPDRS II and III. We predicted
the EQ-5D values with these independent data sets
and calculated R
2 resulting from the predicted and
observed values.
The study protocol for our own data and data from
Spottke et al. [6] was approved by the local ethics
committee and all patients gave informed consent.
Schrag et al. [11] obtained ethics approval from the
National Hospital for Neurology and Neurosurgery
and the Institute of Neurology Joint Medical Ethics
Committee. The study provided by Siderwof et al.
[10] was reviewed by the Research Review Committee
of Pennsylvania Hospital, and informed consent was
obtained from all subjects prior to administration of
study instruments.
Statistical analysis
A correlation analysis was calculated by a two-sided
Spearman’s rank correlation test to determine any
linear relationship between the predictor and the
dependent variable. A multiple linear regression ana-
lysis was applied to develop a prediction rule for
EQ-5D (i.e., Germanindex and Europeanindex)f r o m
the UPDRS and PDQ-8 variables. The interaction
terms and squares of the variables were considered
including PDQ-8- and UPDRS-subscores. Following
the algorithm established by Cheung et al. [12], we
built quadratic terms of these scales to consider
non-linear relationships. We conducted a fractional
polynomial regression analysis [13] to provide an al-
ternative analytical approach to model the non-linear
relationships between the outcomes and predictors.
We investigated a logarithmic relationship and a
relationship up to the third degree between the
EQ-5D and the independent variables. The relation-
ship between EQ-5D and predictor variables was
nonparametrically estimated by a local polynomial
smoothing of a general additive regression without
making a functional assumption about the relation-
ship. This approach serves as a graphical check of
the parametric model fit to the data. In a second
analysis, each EQ-5D dimension item was predicted,
and the EQ-5Dindex values were subsequently calcu-
lated. Several items of the UPDRS II-IV cover similar
aspects as some EQ-5D items (e.g. activities of daily
living/ self care by the UPDRS II or mobility, and
pain by the UPDRS III). To investigate the relevance
on the overall association between the UPDRS II-IV
and the EQ-5D, we repeated our analyses after the
elimination of UPDRS items 9, 10, 11, 12, 13, 14, 15,
17, 22, 29, 30, and 31 from the recalculated UPDRS
II-IV scores.
Four basic regression models were built as follows:
M1 “UPDRS II   III” :
EQ   5D ¼ UPDRS II þ UPDRS III
M2 “UPDRS II   IV” :
EQ   5D ¼ UPDRS II þ UPDRS III þ UPDRS IV
M3 “UPDRS II   IVa   c” :
EQ   5D ¼ UPDRS II þ UPDRS III þ UPDRS IVa þ
UPDRS IVb þ UPDRS IVc
M4 “PDQ   8” :
EQ   5D ¼ PDQ1 þ PDQ2 þ PDQ3 þ PDQ4 þ PDQ5 þ
PDQ6 þ PDQ7 þ PDQ8
The models were constructed applying backward
selection. For the model validation R
2 and root mean
square error (RMS) were calculated. To be consist-
ent with other published work [12,14,15], we consid-
ered values for R
2 ≥0.3 as acceptable and R
2 values
≥0.5 as good predictions.
The alternative model fit was evaluated with the
Pregibon link test [16] and the Bayesian information cri-
terion (BIC). The model specification error was tested
by the Pregibon link test to check the linearity of the
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selection was assessed by the BIC. We graphically con-
ducted a comparison of the linear regression analysis
and factional polynomials against the local polynomial
smoothing.
All analyses were calculated with the statistical pack-
ages STATA and R (Stata 12, StataCorp LP, Texas USA;
R-2.15.1 Comprehensive R Archive Network, Institute
for Mathematics, TU Vienna, Austria).
Results
Seventeen patients were excluded because of missing
data. We therefore evaluated a total of 121 patients.
The mean patient age was 67.1 years (SD 9.1) and
66.1% were males. Approximately 2/3 of the popula-
tion was classified into Hoehn&Yahr (HY) stage II, III
or IV, with 6.6% in stage I and 6.6% in stage V. No
differences in age and sex were observed between in-
cluded and excluded cases but excluded cases had
higher HY stages, with nearly 3/4 of these cases being
in HY stages IV or V.
The correlation analysis demonstrated that the
EQ-5D Germanindex and the EQ-5D Europeanindex were
associated for some variables: PDQ1, PDQ2, UPDRS II,
UPDRS III with the EQ-5D Germanindex,a n dP D Q 1 ,
PDQ2, PDQ7, UPDRS II, UPDRS III with the EQ-5D
Europeanindex (all rs >0.6 and p <0.05).
On average, 50.0% (n=9) of the models analysed in
“UPDRS II-III”, 42.6% (n=23) in “UPDRS II-IV”, 24.3%
(n=118) in “UPDRS II-IVa-c” and 1.5% (n=197) in
“PDQ-8” solely consisted of coefficients with a signifi-
cant p-value (p <0.05). We will refer to these models as
“significant models”.
The equations for best data fit of the EQ-5D Germanindex
were represented by
M1 “UPDRS II   III” :
EQ   5D ¼ 0:9042   0:0001   UPDRS III2
M2 “UPDRS II   IV” :
EQ   5D ¼ 0:9275   0:0001   UPDRS III2   0:0134
 UPDRS IV
M3 “UPDRS II   IVa   c” :
EQ   5D ¼ 0:9628   0:0001   UPDRS III2 þ 0:0031
 UPDRS IVa2   0:0052   UPDRS IVb
2   0:0448
 UPDRS IVc2
M4 “PDQ   8” :
EQ   5D ¼ 0:9298   0:00004   PDQ12   0:00002
 PDQ22   0:00004   PDQ82
Table 1 Results from regression analysis
EQ-5D Germanindex EQ-5D Europeanindex
M1 M2 M3 M4 M1 M2 M3 M4
Intercept 0.904154*** 0.927487*** 0.962811*** 0.9298*** 79.272395*** 76.85026*** 80.05367*** 81.959757***
UPDRS II −0.775300*
1
UPDRS III −0.000129***
2 −0.000111***
2 −0.000106***
2 −0.008005***
2 −0.01006***
2 −0.01022***
2
UPDRS IV −0.013411**
1 −1.52015***
1
UPDRS IVa 0.003055**
2 0.24170*
2
UPDRS IVb −0.005198***
2 −2.23550**
1 ,
UPDRS IVc −0.044820***
2 −3.91892***
2
PDQ1 −0.000043***
2 −0.379520***
1
PDQ2 −0.000023*
2 −0.002511***
2
PDQ3
PDQ4
PDQ5
PDQ6
PDQ7
PDQ8 −0.000035***
2 −0.003005***
2
R
2 0.5377 0.5685 0.7117 0.6034 0.5607 0.5850 0.6840 0.6662
RMS 0.1743 0.1691 0.1394 0.1628 15.7759 15.3327 13.3798 13.7519
Link test 0.068 n.s. 0.053 n.s. 0.33 n.s. 0.053 n.s 0.772 n.s. 0.025 n.s. 0.999 n.s. 0.025 n.s.
Statistics for the regression analysis including the model fit of models achieving a maximum R
2 and minimum root mean square error (RMS);
* represent the level of significance (n.s.: not significant for p ≥0.05, *: p <0.05, **: p <0.01, ***: p <0.001); the numbers indicate the degree of terms included in
the model for maximum R
2 (
1linear terms,
2quadratic terms); PDQx indicates the respective of the eight items of the PDQ-8 questionnaire.
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following:
M1 “UPDRS II   III” :
EQ   5D ¼ 79:272   0:775   UPDRS II   0:008
 UPDRS III2
M2 “UPDRS II   IV” :
EQ   5D ¼ 76:850   0:010   UPDRS III2   1:520
 UPDRS IV
M3 “UPDRS II   IVa   c” :
EQ   5D ¼ 80:054   0:010   UPDRS III2 þ 0:242  
UPDRS IVa2 2:236   UPDRS IVb   3:919  
UPDRS IVc2
M4 “PDQ   8” :
EQ   5D ¼ 81:960:   0:380   PDQ1   0:003   PDQ22  
0:003   PDQ82
The models were compared for the best data fit with
maximum R
2 values, and minimum RMS values. The
model “UPDRS II-IVa-c” showed the best fit for both the
EQ-5D Germanindex and the EQ-5D Europeanindex (R
2 =
0.712 and 0.684, respectively) (Table 1). The same model
also showed the smallest RMS values (0.14 and 13.38, re-
spectively). The R
2 and RMS values for all other models
for the EQ-5D were in the ranges of 0.538-0.603 (R
2)
and 0.16-0.17 (RMS) for the Germanindex and 0.561-
0.666 (R
2) and 13.75 to 15.78 (RMS) the EQ-5D
Europeanindex (Table 1). The elimination of similar items
from the UPDRS II-IV resulted in R
2 values of 0.684 for
the Germanindex and 0.682 for the EQ-5D Europeanindex.
The model structure and complexity was evaluated by
the goodness of the link-test of Pregibon [16] and the
BIC. The link test did not reject the hypothesis of model
misspecification for all models constructed. This result
indicates that the functional relationship was correctly
specified for all significant predictors considered in the
model. The smallest coefficients were observed for the
“UPDRS II-IVa-c” model regardless of the Europeanindex
or Germanindex prediction (Table 1). This result was fur-
ther supported by a small BIC for the M3 model.
The fractional polynomial regression resulted in the
same models with optimal R
2. The original EQ-5D data
and a graphical comparison of the estimated regression
models (linear, fractional polynomial and general addi-
tive regression) are shown in Figure 1.
The regression analysis for the single EQ-5D questions
1–5 resulted in a R
2 of 0.31 for the EQ-5D Europeanindex
and 0.26 for the EQ-5D Germanindex items.
The validation of our results with independent data
from our own (M1 model), from Siderowf et al. [10]
(M1 and M4 models) and Schrag et al. [11] (all models)
showed R
2 values ranging from 0.11 to 0.56 for the
EQ-5D Germanindex and from 0.24 to 0.64 for the EQ-5D
Europeanindex. These results confirm the results (except
for the prediction of the EQ-5D Germanindex by the
UPDRS II-III model) from our primary data showing ro-
bust results and indicating external validity.
Discussion
We present an algorithm for the estimation of the
EQ-5D from the UPDRS parts II-IV and the PDQ-8, both
of which are standard clinical classification schemes that
are widely used in the evaluation of Parkinson’s disease
patients within clinical studies. Our prediction models
based on the UPDRS explained more than 71% and 68%
of the variation and used models having minimal RMS of
0.14 and 13.38 in the EQ-5D Germanindex and EQ-5D
Europeanindex, respectively. The results were reproduced
by our own independent data and data from Siderowf
et al. [10] and Schrag et al. [11]. We note, however, that
the application of empirical utility data is preferable if
available. However, we address an approach to these issues
when utility data are missing.
Our mapping algorithm for the UPDRS compared to the
PDQ-8 explained slightly more of the appearing variance
predicting the EQ-5D (PDQ-8: 60.3% and 66.6%; UPDRS:
71.2% and 68.4% for the EQ-5D Germanindex and the
EQ-5D Europeanindex). This finding was supported by the
RMS (PDQ-8: 0.16 and 13.75, UPDRS: 0.14 and 13.38 for
the EQ-5D Germanindex and EQ-5D Europeanindex). This
result is surprising because we expected the PDQ-8 by
measuring Parkinson specific quality of life to have a
greater conceptual resemblance to the EQ-5D. The frac-
tional polynomial regression tested different types of
models, and we concluded that the “PDQ-8” data have a
poorer fit compared to “UPDRS II-IVa-c”. One possible ex-
planation for this result is the different nature of the items
in the two instruments; the EQ-5D has a stronger focus on
the perceived impaired general health due to the physical
illness, and the PDQ-8 considers more of the social and
psychological consequences of Parkinson’sd i s e a s e .T h e
focus of the UPDRS on physical constraints makes this in-
strument more likely to have a relationship conceptually
closer to the EQ-5D. Additional analyses showed that simi-
lar items in the UPDRS II-IV and the EQ-5D did not have
a relevant impact on the association between the UPDRS
and the EQ-5D, thus supporting our potential explanation.
The link test and the BIC indicated that the model includes
all important terms (see also Figure 1). Although we do not
expect to find a relevant bias, we cannot completely rule
out residual bias and model misspecification. The maximal
R
2 and minimal RMS represent the best fit of the data, but
not necessarily the most logical relationship between the
predictor and the independent variables investigated.
The unexplained variance of approximately 30% may re-
sult from conceptual differences between the scales (e.g.,
in comorbidities such as depression) or differences in the
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Figure 1 Presentation of the EQ-5D data fit for the regression line (left panel: EQ-5D Germanindex; right panel: EQ-5D Europeanindex):
comparison of the fitted values estimated by alternative analytic approaches (dots: EQ-5D values; solid line: fitted regression line by
ordinary linear regression; dash-dot line: fitted regression line by a generalised additive model; dashed line: fitted regression line by
fractional polynomials). The UPDRS II was not presented because its categorical nature led to the accumulation of points by a small
number of values.
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Furthermore regression analysis does not consider
pseudo-correlation or multi-collinearity.
We attempted to detect country-specific responses to
the EQ-5D questionnaire with an analysis of the EQ-5D
with German and European weights, but the marginal
differences indicate the robustness of our models.
In contrast, when the model suggested by Cheung
et al. [12] was applied to our data it failed to result in a
satisfying model fit (R
2 close to zero and RMS = 3651.5),
suggesting that the model is inappropriate for our data.
However, Cheung et al. calculated an Asian EQ-5Dindex,
necessitating a careful comparison between our German
data and Cheung’s et al. results. We therefore expanded
our analysis beyond the work of Cheung et al. and analysed
the quadratic, cubic and logarithmic relationships between
the EQ-5Dindex and PDQ-8 or UPDRS. However, non-
linear effects did not contribute to the association in a
relevant way.
Another recently published study [14] dealt with the
prediction of EQ-5D dimensions from PDQ-39 items
using sophisticated simulation-based methods. The au-
thors showed a better prediction with their method com-
pared to several regression analysis methods. This is
consistent with our results for the prediction of EQ-5D
items 1–5, which resulted in R
2 of 0.26 for the EQ-5D
Germanindex and 0.31 for the EQ-5D Europeanindex.H o w -
ever, the approach described by Borchani et al. is probably
not easily applicable in the clinical setting.
Conclusion
The EQ-5Dindex values were best estimated with a model
based on the UPDRS subscales II-IVa-c regardless of
whether we applied German or European weights to cal-
culate the EQ-5D. The data fit as measured by the max-
imum R
2 and minimum RMS is best for these models.
The prediction rule could be validated with several inde-
pendent data sets, indicating the potential for general use-
fulness. However, the results from the application of the
instrument in large and independent studies should be
reported prior to general application.
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